OBJECTIVE： To validate and evaluate the accuracy of 4 kinds of warfarin genomics maintenance dose prediction model of in Chinese patients. METHODS： 140 patients receiving oral warfarin anticoagulant therapy to keep maintenance dose and 94 healthy volunteers were selected. CYP2C9 and VKORC1 gene polymorphism were detected by gene chip. The characteristics of genotype distribution were analyzed， and the difference of practical maintenance dose were investigated among different genotype patients. The dose of warfarin was calculated by using IWPC， Gage， Huang and Miao dose prediction model. The relationship of warfarin dose with practical maintenance dose was investigated， and the accuracy of prediction model was evaluated. RESULTS： CYP2C9 and VKORC1 gene frequency of 234 volunteers were in line with Hardy-Weinberg balance. Of 140 patients， actual maintenance dose in CYP2C9*1/*1 genotype was higher than in CYP2C9*1/*3 genotype， with statistical significance （P＜0.001）； actual maintenance dose in VKORC1 AA genotype was lower than in GA and GG genotype， with statistical significance （P＜0.001）. IWPC， Gage， Huang and Miao dose prediction models were correlated with actual maintenance dose （R2＝0.701， 0.166， 0.664 and 0.605， all P＜0.001）. When actual maintenance dose ≤2.5 mg/d， there was statistical significance between 4 dose prediction models and actual dose （all P＜0.05）； when actual maintenance dose ranged ＞2.5-＜5 mg/d， there was statistical significance between Gage， Huang and Miao dose prediction models and actual dose （all P＜0.05）； there was no statistical significance between IWPC dose prediction model and actual dose （P＞0.05）； when actual maintenance dose≥5 mg/d， there was statistical significance between Huang and Miao model and actual dose （all P＜0.05）； there was no statistical significance between IWPC and Gage model and actual dose （all P＞0.05）. CONCLUSIONS： There is significant difference in actual maintenance dose between CYP2C9 genotype and VKORC1 genotype； IWPC model can predict the dose of warfarin in patients with maintenance dose of ＞2.5-＜5 mg/d well， which is of potential significance to safety and effectiveness improvement of warfarin anticoagulant therapy.